Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer
Journal of Medicinal Chemistry · 11.01.2024 · 67 (1) · 479-491
DOI: 10.1021/acs.jmedchem.3c01693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 18.12.2023. Verfasst von Chen Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, P. R. China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Triple Negative Breast Neoplasms, Prodrugs. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: China Pharmaceutical University, Natural Science Foundation of Xinjiang Uygur Autonomous Region, National Natural Science Foundation of China.
Abstract (Originalsprache)
The platinum(IV) prodrug strategy is attractive for the synergistic antitumor effect. High levels (>400 nM) of nitric oxide (NO) exert promising cancer inhibition effects via multiple mechanisms. Herein, we designed and synthesized a new group of integrated bioorthogonal self-catalyzed NO donor/Pt(IV) prodrugs bearing long alkyl chains to enhance the stability in circulation, while the cytoplasmic reductants trigger cascade activation to release Pt and NO in tumor cells. Specifically, compound 10c exhibited an improved stability, favorable pharmacokinetic properties (AUC(0-t) of 2210.10 h*ng/mL), potent anti-triple-negative breast cancer (TNBC) effects (71.08% tumor growth inhibition (TGI) against the MDA-MB-231 xenograft model), potent in vivo anti-TNBC lung metastasis activity, and acceptable low toxicity. Importantly, NO released from 10c leads to the S-nitrosation of metal transporters Atox1&ATP7a in TNBC cells, which increases the Pt retention and inhibits lysyl oxidase, generating synergistic tumoricidal and antimetastatic activity. These results may inspire further study on the synergistical therapy of Pt and NO for the treatment of TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 211198, P. R. China.
- Xinjiang Key Laboratory of Neurological Disorder Research, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830028, P. R. China.
- School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, P. R. China.
- School of Pharmacy, Key Laboratory of Active Components of Xinjiang Natural Medicine and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Xinjiang Medical University…
ORCID-Profile: Hui Ye, Juan Zhang, Yihua Zhang, Jianbing Wu, Zhangjian Huang
Förderung
- China Pharmaceutical University
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- National Natural Science Foundation of China
- Science and Technology Supporting Xinjiang Project
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia
Zitieren
APA
Zhang, C., Zhu, J., Yuan, X., Yan, Z., Ye, H., Xiong, T., Xu, A., Li, C., Ji, D., Yang, S., Zhang, J., Zhang, Y., Wu, J., & Huang, Z. (2024). Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 67(1), 479-491. https://doi.org/10.1021/acs.jmedchem.3c01693
Vancouver
Zhang C, Zhu J, Yuan X, Yan Z, Ye H, Xiong T, et al. Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2024;67(1):479-491. doi:10.1021/acs.jmedchem.3c01693
BibTeX
@article{Zhang2024,
author = {Zhang, Chen and Zhu, Jie and Yuan, Xun and Yan, Zhengsheng and Ye, Hui and Xiong, Tao and Xu, Anning and Li, Cunrui and Ji, Duorui and Yang, Shan and Zhang, Juan and Zhang, Yihua and Wu, Jianbing and Huang, Zhangjian},
title = {Development of Integrated Bioorthogonal Self-Catalyzed NO Donor/Platinum(IV) Prodrugs for Synergistical Intervention against Triple-Negative Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {1},
pages = {479--491},
doi = {10.1021/acs.jmedchem.3c01693}
}
EUVIMED